Thrombin inhibitor

Thrombin inhibitor

Thrombin inhibitors are one type of anticoagulant medication, used to help prevent formation of harmful blood clots in the body by blocking the activity of thrombin.
References in periodicals archive ?
The HemosIL Rivaroxaban Testing Solution is the second assay IL has commercialized in their DOAC Assay Panel, following the introduction of their HemosIL Direct Thrombin Inhibitor Assay for measurement of dabigatran (Pradaxa[sup.
The RE-SPECT ESUS study (Randomized Evaluation in Secondary stroke PrEvention Comparing the Thrombin inhibitor dabigatran etexilate versus acetylsalicylic acid (ASA) in Embolic Stroke of Undetermined Source) aims to include 6,000 patients from study sites in Asia, Europe, North and South America.
1] The first novel anticoagulant (NOAC) and direct thrombin inhibitor (DTI), lepirudin, originates from 1998, when its intravenous form was approved for the use of clinically relevant heparin-induced thrombocytopenia (HIT).
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
21) The Thrombin inhibitor management (TIM)-ECT was developed as a poinl-of-care test in Europe and is based on the same coagulation principles as the ECT, but in a one-step, dry chemistry platform.
The storage and handling requirements for Pradaxa, a direct thrombin inhibitor, are listed on the product label and medication guide, but "FDA is concerned that these requirements are not commonly known and are not being followed by Pradaxa users and by pharmacists,' the statement said.
2,5,10,17) A direct thrombin inhibitor (DTI) must be administered for a minimum of 7 days.
Ximelagatran, an oral direct thrombin inhibitor has the potential to be an alternative choice in the prevention and therapy of thromboembolism related with atrial fibrillation.
Four SPORTIF (Stroke Prevention by Oral Thrombin Inhibitor in atrial Fibrillation) trials have been completed or are under way.
Since ANGIOMAX is a small-molecule, direct inhibitor of thrombin, it can inhibit both fluid-phase (inactive) or clot-bound (active) thrombin, whereas heparin, an indirect thrombin inhibitor, can only inhibit fluid-phase thrombin and its action can be impaired by other elements found in blood.
Desirudin was the first direct thrombin inhibitor (DTI) approved for DVT prophylaxis in Europe, where it has been on the market for over 10 years under the trade name Revasc([R]).
Pradaxa, a direct thrombin inhibitor (DTI), was the first widely approved drug in a new generation of direct oral anticoagulants, available to address the high unmet medical need in the prevention and treatment of acute and chronic thromboembolic diseases.